Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

TERT promoter mutations rather than methylation are the main mechanism for TERT upregulation in adult gliomas.

Arita H, Narita Y, Takami H, Fukushima S, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Shibui S, Ichimura K.

Acta Neuropathol. 2013 Dec;126(6):939-41. doi: 10.1007/s00401-013-1203-9. Epub 2013 Oct 31. No abstract available.

PMID:
24174165
2.

Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.

Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP, Kawahara N, Shibui S, Ichimura K.

Acta Neuropathol. 2013 Aug;126(2):267-76. doi: 10.1007/s00401-013-1141-6. Epub 2013 Jun 14.

PMID:
23764841
3.

Association of Telomerase Reverse Transcriptase Promoter Mutations with the Prognosis of Glioma Patients: a Meta-Analysis.

Wang X, Li X, Xu F, Zhang Y, Liu H, Tao Y.

Mol Neurobiol. 2016 May;53(4):2726-32. doi: 10.1007/s12035-015-9400-2. Epub 2015 Sep 8.

PMID:
26351078
4.

Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system.

Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, Jones DT, Kool M, Northcott PA, Wiestler B, Böhmer K, Meyer J, Mawrin C, Hartmann C, Mittelbronn M, Platten M, Brokinkel B, Seiz M, Herold-Mende C, Unterberg A, Schittenhelm J, Weller M, Pfister S, Wick W, Korshunov A, von Deimling A.

Acta Neuropathol. 2013 Dec;126(6):907-15. doi: 10.1007/s00401-013-1195-5. Epub 2013 Oct 24.

PMID:
24154961
5.

Promoting a new brain tumor mutation: TERT promoter mutations in CNS tumors.

Reitman ZJ, Pirozzi CJ, Yan H.

Acta Neuropathol. 2013 Dec;126(6):789-92. doi: 10.1007/s00401-013-1207-5. No abstract available.

6.

TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas.

Gao K, Li G, Qu Y, Wang M, Cui B, Ji M, Shi B, Hou P.

Oncotarget. 2016 Feb 23;7(8):8712-25. doi: 10.18632/oncotarget.6007.

7.

TERT promoter mutations and telomere length in adult malignant gliomas and recurrences.

Heidenreich B, Rachakonda PS, Hosen I, Volz F, Hemminki K, Weyerbrock A, Kumar R.

Oncotarget. 2015 Apr 30;6(12):10617-33.

8.

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.

Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, Netto GJ, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, Shih IeM, Theodorescu D, Torbenson MS, Velculescu VE, Wang TL, Wentzensen N, Wood LD, Zhang M, McLendon RE, Bigner DD, Kinzler KW, Vogelstein B, Papadopoulos N, Yan H.

Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6021-6. doi: 10.1073/pnas.1303607110. Epub 2013 Mar 25.

9.

Molecular categorisation of gliomas.

Burki TK.

Lancet Oncol. 2015 Jul;16(7):e320. doi: 10.1016/S1470-2045(15)00073-X. Epub 2015 Jun 18. No abstract available.

PMID:
26095778
10.

TERT mutation in glioma: Frequency, prognosis and risk.

Yuan Y, Qi C, Maling G, Xiang W, Yanhui L, Ruofei L, Yunhe M, Jiewen L, Qing M.

J Clin Neurosci. 2016 Apr;26:57-62. doi: 10.1016/j.jocn.2015.05.066. Epub 2016 Jan 4.

PMID:
26765760
11.

Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study.

Castelo-Branco P, Choufani S, Mack S, Gallagher D, Zhang C, Lipman T, Zhukova N, Walker EJ, Martin D, Merino D, Wasserman JD, Elizabeth C, Alon N, Zhang L, Hovestadt V, Kool M, Jones DT, Zadeh G, Croul S, Hawkins C, Hitzler J, Wang JC, Baruchel S, Dirks PB, Malkin D, Pfister S, Taylor MD, Weksberg R, Tabori U.

Lancet Oncol. 2013 May;14(6):534-42. doi: 10.1016/S1470-2045(13)70110-4. Epub 2013 Apr 16.

PMID:
23598174
12.

TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations.

Kim YH, Pierscianek D, Mittelbronn M, Vital A, Mariani L, Hasselblatt M, Ohgaki H.

J Clin Pathol. 2011 Oct;64(10):850-2. doi: 10.1136/jclinpath-2011-200133. Epub 2011 Jun 20.

PMID:
21690245
13.

TERT promoter mutations in primary and secondary glioblastomas.

Nonoguchi N, Ohta T, Oh JE, Kim YH, Kleihues P, Ohgaki H.

Acta Neuropathol. 2013 Dec;126(6):931-7. doi: 10.1007/s00401-013-1163-0. Epub 2013 Aug 17.

PMID:
23955565
14.

Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.

Takahashi Y, Nakamura H, Makino K, Hide T, Muta D, Kamada H, Kuratsu J.

World J Surg Oncol. 2013 Oct 25;11:284. doi: 10.1186/1477-7819-11-284.

15.

The Sensitive Detection of Telomerase Reverse Transcriptase Promoter Mutation by Amplification Refractory Mutation System-PCR.

Liu J, Zhao Z, Sun M, Chen K, Yuan W, Jiang G.

Genet Test Mol Biomarkers. 2016 Feb;20(2):90-3. doi: 10.1089/gtmb.2015.0229. Epub 2016 Jan 7.

PMID:
26741813
16.

Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution.

Boots-Sprenger SH, Sijben A, Rijntjes J, Tops BB, Idema AJ, Rivera AL, Bleeker FE, Gijtenbeek AM, Diefes K, Heathcock L, Aldape KD, Jeuken JW, Wesseling P.

Mod Pathol. 2013 Jul;26(7):922-9. doi: 10.1038/modpathol.2012.166. Epub 2013 Feb 22.

17.

Absence of TERT promoter mutations in primary melanocytic tumours of the central nervous system.

Gessi M, van de Nes J, Griewank K, Barresi V, Buckland ME, Kirfel J, Caltabiano R, Hammes J, Lauriola L, Pietsch T, Waha A.

Neuropathol Appl Neurobiol. 2014 Oct;40(6):794-7. doi: 10.1111/nan.12138. No abstract available.

PMID:
24645797
18.

TERT hypermethylation: biomarker in paediatric brain tumours.

Diede SJ.

Lancet Oncol. 2013 May;14(6):447-8. doi: 10.1016/S1470-2045(13)70124-4. Epub 2013 Apr 16. No abstract available.

PMID:
23598170
19.

Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis.

Laffaire J, Everhard S, Idbaih A, Crinière E, Marie Y, de Reyniès A, Schiappa R, Mokhtari K, Hoang-Xuan K, Sanson M, Delattre JY, Thillet J, Ducray F.

Neuro Oncol. 2011 Jan;13(1):84-98. doi: 10.1093/neuonc/noq110. Epub 2010 Oct 5.

20.

High incidence of TERT mutation in brain tumor cell lines.

Johanns TM, Fu Y, Kobayashi DK, Mei Y, Dunn IF, Mao DD, Kim AH, Dunn GP.

Brain Tumor Pathol. 2016 Jul;33(3):222-7. doi: 10.1007/s10014-016-0257-5. Epub 2016 Mar 9.

PMID:
26960334

Supplemental Content

Support Center